The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)
tumors recently have been reported that can benefit from immunotherapy, and MSI can be …

Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Metastatic castration-resistant prostate cancer (mCRPC) is immunologically" cold" and
predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Tumors evolve in close interaction with their microenvironment, which encompasses a
continual tension between the developing tumor and the host immune system. Clinical trials …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …